Vivek Subbiah, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the impact of the American Association of Cancer Research’s Project GENIE (Genomics Evidence Neoplasia Information Exchange) on precision oncology for ultra-rare sarcomas. A major challenge in precision medicine is that no single institution can sequence and treat enough patients to improve clinical decision-making independently, and this is especially problematic in ultra-rare sarcomas such as perivascular epithelioid cell tumors (PEComa). AACR Project GENIE is a publicly accessible international cancer registry of real-world data assembled through data sharing between 19 of the leading cancer centers in the world and will be instrumental in driving precision oncology in this field. This interview took place at the American Association for Cancer Research Annual Meeting in New Orleans, LA.
